Abstract:Rett syndrome (RTT) has enjoyed remarkable progress in achieving specific therapies. RTT, a unique neurodevelopmental disorder first described in 1966, progressed slowly until the landmark paper of Hagberg and colleagues in 1983. Thereafter, rapid advances were achieved including the development of specific diagnostic criteria and the active search for a genetic etiology, resulting 16 years later in identification of variants in the methyl-CpG-binding protein ( MECP2 ) gene located at Xq28. Shortly thereafter, the NIH Office of Rare Diseases funded the RTT Natural History Study (NHS) in 2003, initiating the acquisition of natural history data on clinical features from a large population of individuals with RTT. This information was essential for advancement of clinical trials to provide specific therapies for this disorder. In the process, the International Rett Syndrome Association (IRSA) was formed (now the International Rett Syndrome Foundation—IRSF), which participated directly in encouraging and expanding enrollment in the NHS and, subsequently, in developing the SCOUT program to facilitate testing of potential therapeutic agents in a mouse model of RTT. The overall objective was to review clinical characteristics developed from the NHS and to discuss the status of specific therapies for this progressive neurodevelopmental disorder. The NHS study provided critical information on RTT: growth, anthropometrics, longevity, key comorbidities including epilepsy, breath abnormalities, gastroesophageal dysfunction, scoliosis and other orthopedic issues, puberty, behavior and anxiety, and progressive motor deterioration including the appearance of parkinsonian features. Phenotype–genotype correlations were noted including the role of X chromosome inactivation. Development of clinical severity and quality of life measures also proved critical for subsequent clinical trials. Further, development of biochemical and neurophysiologic biomarkers offered further endpoints for clinical trials. Initial clinical trials prior to the NHS were ineffective, but advances resulting from the NHS and other studies worldwide promoted significant interest from pharmaceutical firms resulting in several clinical trials. While some of these have been unrewarding such as sarizotan, others have been quite promising including the approval of trofinetide by the FDA in 2023 as the first agent available for specific treatment of RTT. Blarcamesine has been trialed in phase 3 trials, 14 agents have been studied in phase 2 trials, and 7 agents are being evaluated in preclinical/translational studies. A landmark study in 2007 by Guy et al. demonstrated that activation of a normal MECP2 gene in a null mouse model resulted in significant improvement. Gene replacement therapy has advanced through translational studies to two current phase 1/2 clinical trials (Taysha102 and Neurogene-401). Additional genetic therapies are also under study including gene editing, RNA editing, and X-chromosome reactivation. Taken together, progress in understanding and treating RTT over the past 40 years has been remarkable. This suggests that further advances can be expected.

InterRett, a model for international data collection in a rare genetic disorder

Rett syndrome in Ireland: a demographic study

Genotype and Early Development in Rett Syndrome: the Value of International Data.

Epidemiology of Rett syndrome: a population-based registry

Using a large international sample to investigate epilepsy in Rett syndrome.

Genetic Instability and Disease Progression of Indian Rett Syndrome Patients

Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study

Associations between genotype, phenotype and behaviours measured by the Rett syndrome behaviour questionnaire in Rett syndrome

Molecular characteristics of Chinese patients with Rett syndrome.

Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database

Rett syndrome: An autoimmune disease?

Rett Syndrome: The Emerging Landscape of Treatment Strategies

Barriers to Diagnosis of a Rare Neurological Disorder in China—Lived Experiences of Rett Syndrome Families

Prevalence of Endocrinopathies in a Cohort of Patients with Rett Syndrome: A two-Center Observational Study

Prevalence of orthopaedic conditions in Rett syndrome: a systematic review and meta‐analysis

Transcriptome level analysis in Rett syndrome using human samples from different tissues

X Chromosome Inactivation in Rett Syndrome and Its Correlations with MECP2 Mutations and Phenotype.

Multimodal Neuroimaging in Rett Syndrome With MECP2 Mutation

Evaluation of seizure semiology, genetics, magnetic resonance imaging, and electroencephalogram findings in children with Rett syndrome: A multicenter retrospective study

Orthopedic Conditions and Interplay with Functional Abilities and MECP2 Variant Subtype in Rett Syndrome Patients

[Application of Long Range Polymerase Chain Reaction and DNA Direct Sequencing in Diagnosis of Rett Syndrome].